Prospective study for assessing the disease activity of Crohn's disease by using LRG and fecal calprotectin.

Prospective study for assessing the disease activity of Crohn's disease by using LRG and fecal calprotectin. - Prospective study for assessing the disease activity of CD by using LRG and FC.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000049128

Enrollment

100

Registered

2022-10-05

Start date

2022-10-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn&#39

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with inflammatory bowel disease

Exclusion criteria

Exclusion criteria: Patients under 20 years old Contraindicated patients for endoscopy Patients with autoimmune diseases other than inflammatory bowel disease Patients with malignancy Patients that the doctor deems inappropriate

Design outcomes

Primary

Measure	Time frame
Predictive ability of LRG and fecal calprotectin for mucosal healing in Crohn's disease.	—

Secondary

Measure	Time frame
Correlation between LRG or fecal calprotectin and endoscopic activity in Crohn's disease.	—

Countries

Japan

Contacts

Public ContactTatsuya Kawamura

Nagoya University Graduate School of Medicine Department of Gastroenterology and Hepatology

kawamura.tatsuya.849@mail.aichi-med-u.ac.jp052-741-2111

Outcome results